Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

This phase II trial tests alternate doses and dosing schedules of belantamab mafodotin in treating patients with triple-class multiple myeloma that has come back (after a period of improvement) (recurrent) and/or does not respond to treatment (or that has not responded to previous treatment) (refractory). Belantamab mafodotin is a monoclonal antibody, belantamab, linked to a chemotherapy drug, mafodotin. Belantamab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as BCMA receptors, and delivers mafodotin to kill them. Thi

Trial Details

NCT ID
NCT05847569
Phase
PHASE2
Sponsor
Mayo Clinic
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Belantamab Mafodotin
  • Biospecimen Collection
  • Bone Marrow Aspirate
  • Bone Marrow Biopsy
  • Computed Tomography
  • Magnetic Resonance Imaging
Locations (sample)
  • Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

  • Age \>= 18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2
  • Histologically or cytologically confirmed diagnosis of multiple myeloma (MM), as defined in International Myeloma Working Group (IMWG) criteria, and:
  • If patients have undergone stem cell transplantation (SCT), day 0 of SCT must be \> 100 days prior to registration to be eligible for the study

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →